Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Wins EU Fast-Track Status For CAR-T Therapy Cilta-Cel

Filing Of Potential Multiple Myeloma Treatment Planned For H1

Executive Summary

Three requests for the accelerated assessment of planned EU marketing applications were considered by the European Medicines Agency last month.

You may also be interested in...



EU Accelerated Assessment Tracker

One out of seven requests for the accelerated assessment of planned EU marketing authorization applications is known to have been granted this year to date.

EMA PRIME Wins For Bispecific Antibodies & Another Gene Therapy

Just three of the 13 applications that the European Medicines Agency most recently reviewed for entry onto its priority medicines scheme made the grade.

Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race

Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel